Agios Pharmaceuticals’ (AGIO) Hold (C-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their hold (c-) rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Wednesday morning,Weiss Ratings reports.

AGIO has been the subject of a number of other research reports. Bank of America dropped their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Scotiabank dropped their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. HC Wainwright restated a “buy” rating and set a $56.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Finally, Zacks Research downgraded Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $40.61 on Wednesday. The stock has a fifty day moving average price of $37.89 and a two-hundred day moving average price of $34.16. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market cap of $2.36 billion, a price-to-earnings ratio of 3.69 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. As a group, research analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,085 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer directly owned 123,528 shares of the company’s stock, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the transaction, the insider directly owned 868 shares of the company’s stock, valued at approximately $32,003.16. The trade was a 90.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,482 shares of company stock valued at $864,025. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 8,088 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of Agios Pharmaceuticals by 5.8% during the first quarter. Harbor Capital Advisors Inc. now owns 35,729 shares of the biopharmaceutical company’s stock worth $1,047,000 after buying an additional 1,962 shares during the period. CWM LLC boosted its position in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 996 shares during the period. Victory Capital Management Inc. boosted its position in shares of Agios Pharmaceuticals by 28.8% during the first quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 1,964 shares during the period. Finally, GW&K Investment Management LLC boosted its position in shares of Agios Pharmaceuticals by 19.6% during the first quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock worth $23,954,000 after buying an additional 134,063 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.